文献速递血栓与止血

实体瘤输液港患者的癌症相关血栓形成:一项前瞻性多中心法国队列研究(ONCOCIP)

Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP).
PubMed 文献 · Blood · 2018-07-06

ONCOCIP是一项前瞻性多中心队列研究,连续纳入3032例置入输液港的实体瘤成人患者并随访12个月。12个月内导管相关血栓发生率为3.8%(n=111),非导管相关静脉血栓栓塞为9.6%(n=276);多因素分析显示,经头静脉置管可预测导管相关血栓,持续抗血小板治疗具有保护作用,而高龄、既往静脉血栓栓塞、肿瘤部位、化疗前低血红蛋白或白细胞升高是非导管相关静脉血栓栓塞的危险因素。

要点

  • 12个月内导管相关血栓发生率为3.8%(n=111),非导管相关静脉血栓栓塞为9.6%(n=276)。
  • 经头静脉置管可预测导管相关血栓,持续抗血小板治疗具有保护作用。
  • 非导管相关静脉血栓栓塞的危险因素包括高龄、既往静脉血栓栓塞、肿瘤部位、化疗前低血红蛋白或白细胞升高。

核心结论

  • 这项大型前瞻性队列研究显示,置入输液港的实体瘤患者静脉血栓栓塞发生率较高。
  • 导管相关血栓与非导管相关静脉血栓栓塞的危险因素不同。

研究设计与样本

  • 前瞻性多中心队列研究(ONCOlogie et Chambres ImPlantables,ONCOCIP),连续纳入置入输液港的实体瘤成人患者,随访12个月。
  • 共纳入3032例患者,中位年龄63岁,女性占58%。
  • 所有事件均经客观确认并由中心统一裁定,发生率评估整合了死亡的竞争风险。

主要发现

  • 肿瘤部位以乳腺(33.7%)、肺(18.5%)和结直肠(15.6%)最常见,43.2%的患者为转移性肿瘤,97.1%接受化疗。
  • 12个月时48例(1.6%)失访,656例(24.6%)死亡。
  • 12个月内导管相关血栓发生率为3.8%(n=111),非导管相关静脉血栓栓塞为9.6%(n=276)。
  • 多因素分析显示,经头静脉置管可预测导管相关血栓,持续抗血小板治疗具有保护作用。
  • 非导管相关静脉血栓栓塞的危险因素为高龄、既往静脉血栓栓塞、肿瘤部位,以及化疗前低血红蛋白水平或白细胞计数升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The need to accurately identify cancer outpatients at high risk of thrombotic complications is still unmet. In a prospective, multicenter cohort study (ONCOlogie et Chambres ImPlantables [ONCOCIP]), consecutive adult patients with a solid tumor and implanted port underwent 12-month follow-up. Our primary objective was to identify risk factors for (1) catheter-related thrombosis, defined as ipsilateral symptomatic upper-limb deep-vein thrombosis with or without pulmonary embolism, and (2) venous thromboembolism other than catheter-related, defined as any symptomatic superficial- or deep-vein thrombosis (other than catheter-related) or pulmonary embolism, and incidental pulmonary embolism. All events were objectively confirmed and centrally adjudicated. Rate assessments integrated competing risk of death. Overall, 3032 patients were included (median age: 63 years; women: 58%). The most frequent cancer locations were breast (33.7%), lung (18.5%), and colorectal (15.6%), cancer being metastatic in 43.2% of patients. Most patients (97.1%) received chemotherapy. By 12 months, 48 (1.6%) patients had been lost to follow-up and 656 (24.6%) had died; 3.8% (n = 111) of patients had experienced catheter-related thrombosis, and 9.6% (n = 276) venous thromboembolism other than catheter-related. By multivariate analysis, use of cephalic vein for catheter insertion predicted catheter-related thrombosis, whereas ongoing antiplatelet therapy was protective; risk factors for venous thromboembolism other than catheter-related were advanced age, previous venous thromboembolism, cancer site, and low hemoglobin level or increased leukocyte count before chemotherapy. In conclusion, this large prospective cohort study showed a high rate of venous thromboembolism in patients with a solid tumor and implanted port. Risk factors for catheter-related thrombosis differed from those for venous thromboembolism not catheter-related. This trial was registered at www.clinicaltrials.gov as #NCT02025894.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Decousus H, Bourmaud A, Fournel P, et al. Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOCIP). Blood. 2018. PMID: 29980524. doi:10.1182/blood-2018-03-837153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。